Equity Profile

VKTX

Viking Therapeutics, Inc.

Health CareBiotechnology$3.8B

Jul29Wed

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Viking Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for metabolic and endocrine disorders....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely watch.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and drive sales, which is essential for long-term success.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

VKTX Q2-2026 Earnings Preview

Context

Company Snapshot

Viking Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for metabolic and endocrine disorders. With a market cap of $4 billion, its work is crucial in addressing significant health issues and advancing treatment options in the healthcare sector.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

25%

Avg EPS Surprise

-19.44%

Avg Stock Reaction

-0.60%

Last Quarter Recap

In Q1-2026, Viking Therapeutics reported an EPS of -$1.37, missing estimates by a significant margin. The stock reacted negatively, dropping 3.27% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall expectations for Viking Therapeutics are cautious, given their recent earnings misses and lack of analyst estimates. Investors are looking for signs of improvement in profitability and revenue.

Bull Case

If Viking can demonstrate a turnaround in its earnings and show positive revenue growth, it could regain investor confidence and drive the stock higher.

Bear Case

Continued losses and missed expectations could lead to further declines in stock price, especially if the company fails to provide a clear path to profitability.

Expectations

Two Questions That Matter

The print will turn on these two things.

What specific steps is Viking taking to improve its EPS and reduce losses?

Investors will closely watch for any commitments or strategies that could signal a path to profitability, which is crucial for future growth.

How is Viking's revenue expected to change in the upcoming quarters?

Revenue growth is vital for the company's sustainability, and any guidance on this front will significantly impact investor sentiment.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Viking's potential for a turnaround, as recent performance metrics do not fully capture the company's ongoing development efforts and pipeline potential.

Supporting Evidence

The options market is pricing in a 26% move, indicating that significant volatility is expected, which may not align with the current consensus.

Viking's historical performance shows that even with misses, the stock has occasionally rebounded, suggesting resilience.

Key Risk

If Viking demonstrates a clearer path to revenue growth, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter revolves around whether Viking can demonstrate a clear path to improving its financial performance.

Bull Confirmed If

A reduction in EPS losses to below -$1.20 would indicate progress towards profitability.

Bear Confirmed If

If EPS remains above -$1.50, it could signal ongoing financial struggles.

Pre-Earnings Positioning

Options Market

Implied Move

±26.04%

Historical Avg

±2.8%

Pricing rich

The options market is pricing in a significant potential move, indicating that investors expect volatility around the earnings report.

Options are pricing ±26.0% while VKTX has averaged ±2.8% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.7%

30d HV

44.1%

Calls (506K)P/C Ratio: 0.09Puts (79K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich setup in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 3.6%, with a raw directional average of -1.3% (modestly negative historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Viking beats expectations and raises guidance, history suggests a potential stock increase of around 2.79%, confirming a positive turnaround narrative.

In-Line / Cautious

If results are in line with expectations but lack strong guidance, the stock may see muted reactions as investors remain cautious.

Miss

A miss on earnings could lead to a decline, with historical data suggesting a potential drop of around 0.01%.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on Viking's product pipeline and expected timelines for new therapies.
2Details on cost management strategies to improve EPS.
3Insights into market demand for Viking's therapies and how that might impact revenue.
4Management's outlook on competitive pressures in the biotechnology space.
5Any partnerships or collaborations that could enhance growth prospects.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Jul27

DYNBMO

Dyne Therapeutics, Inc.

PreviewView

Jul27

ARLPBMO

Company Snapshot

Viking Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for metabolic and endocrine disorders....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely watch.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and drive sales, which is essential for long-term success.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

VKTX Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

25%

Avg EPS Surprise

-19.44%

Avg Stock Reaction

-0.60%

Last Quarter Recap

In Q1-2026, Viking Therapeutics reported an EPS of -$1.37, missing estimates by a significant margin. The stock reacted negatively, dropping 3.27% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Bull Case

If Viking can demonstrate a turnaround in its earnings and show positive revenue growth, it could regain investor confidence and drive the stock higher.

Bear Case

Continued losses and missed expectations could lead to further declines in stock price, especially if the company fails to provide a clear path to profitability.

Expectations

Two Questions That Matter

The print will turn on these two things.

What specific steps is Viking taking to improve its EPS and reduce losses?

Investors will closely watch for any commitments or strategies that could signal a path to profitability, which is crucial for future growth.

How is Viking's revenue expected to change in the upcoming quarters?

Revenue growth is vital for the company's sustainability, and any guidance on this front will significantly impact investor sentiment.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Viking's potential for a turnaround, as recent performance metrics do not fully capture the company's ongoing development efforts and pipeline potential.

Supporting Evidence

The options market is pricing in a 26% move, indicating that significant volatility is expected, which may not align with the current consensus.

Viking's historical performance shows that even with misses, the stock has occasionally rebounded, suggesting resilience.

Key Risk

If Viking demonstrates a clearer path to revenue growth, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter revolves around whether Viking can demonstrate a clear path to improving its financial performance.

Bull Confirmed If

A reduction in EPS losses to below -$1.20 would indicate progress towards profitability.

Bear Confirmed If

If EPS remains above -$1.50, it could signal ongoing financial struggles.

Pre-Earnings Positioning

Options Market

Implied Move

±26.04%

Historical Avg

±2.8%

Pricing rich

The options market is pricing in a significant potential move, indicating that investors expect volatility around the earnings report.

Options are pricing ±26.0% while VKTX has averaged ±2.8% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.7%

30d HV

44.1%

Calls (506K)P/C Ratio: 0.09Puts (79K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich setup in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Viking beats expectations and raises guidance, history suggests a potential stock increase of around 2.79%, confirming a positive turnaround narrative.

In-Line / Cautious

If results are in line with expectations but lack strong guidance, the stock may see muted reactions as investors remain cautious.

Miss

A miss on earnings could lead to a decline, with historical data suggesting a potential drop of around 0.01%.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on Viking's product pipeline and expected timelines for new therapies.
2Details on cost management strategies to improve EPS.
3Insights into market demand for Viking's therapies and how that might impact revenue.
4Management's outlook on competitive pressures in the biotechnology space.
5Any partnerships or collaborations that could enhance growth prospects.